


IFW
30

Docket Number: 037003-0280728

PATENT APPLICATION



Client Reference: 2000-30-0513A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

Mitchell REFF

Group Art Unit: 1644

Application No.: 09/982,849

Examiner: Ronald B. Schwadron

Filed: October 22, 2001

Confirmation No.: 7677

For: VARIANT IgG3 RITUXAN AND THERAPEUTIC USE THEREOF

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO Form-1449. One copy of each reference is submitted herewith. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed before the mailing date of the first official action on the merits in the present application. No certification or fee is required.

Respectfully submitted,

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944

Date: June 14, 2003
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/JBM:ntb

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**



Date: June 14, 2003

Page 1 of 2

Applicant: MITCHELL REFF

Appln. No.: 09/982,849

Filing Date: October 22, 2001

Examiner: R. Schwadron Group Art Unit: 1644

U.S. PATENT DOCUMENTS


Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)
	AR 4,816,567	03/1989	Cabilly
	BR 5,500,362	03/1996	Robinson
	CR 5,595,721	01/1997	Kaminski
	DR 5,677,180	10/1997	Robinson
	ER 5,721,108	02/1998	Robinson
	FR 5,736,137	04/1998	Anderson
	GR 5,776,456	07/1998	Anderson
	HR 5,843,439	12/1998	Anderson

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	IR					
	JR					
	KR					
	LR					
	MR					

OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

NR	Idec Pharmaceuticals and Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).
OR	Biogen Idec v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).
PR	Cook et al., "Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation," <i>Lancet</i> , 1999, 354(9191):1698-1699.
QR	Demidem et al., "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs," <i>Cancer Biother Radiopharm</i> , 1997, 12(3):177-186.
RR	Hoffman et al., "Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine," <i>Br J Haematol</i> , 2000, 109(4):900-901.
SR	Keating et al., "Chronic lymphocytic leukemia," <i>Semin Oncol</i> , 1999, 26:5 Suppl 14:107-114.
TR	Kuehnle et al., "CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation," <i>Blood</i> , 2000, 95(4):1502-1505.
UR	Kyle et al., "Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral clorambucil" <i>Br J Haematol</i> , 2000, 108:4 737-742.
VR	Maloney et al., "The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines," <i>Blood</i> , 1996, 88(10):637a (#2535).
WR	Morrison et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc Natl Acad Sci USA</i> , 1984, 81(21):6851-6855.
XR	Piascik, "New therapeutic monoclonal antibodies target kidney transplant rejection and cancer," <i>J Am Pharm Assoc</i> , 1998, 38(3):379-380.
YR	Press et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> , 1987, 69(2):584-591.



ZR	Ratanatharathorn et al., "Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host-disease," <i>Annals of Internal Medicine</i> , 2000, 133:275-279.
AAR	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> , 1994, 83(2):435-445.
BBR	Treon et al., "Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy," <i>Semin Oncol.</i> , 1999, 26 (5 Suppl 14):97-106.
CCR	Treon et al., "Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens," <i>Ann Oncol</i> , 2000, 11 Suppl 1:107-111.
Examiner	
Date Considered:	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	